4 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
IFRX
24 Apr 24
and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab
- Prev
- 1
- Next